


• American society for reproductive medicine (2001): Intra cytoplasmic sperm injection fact sheet 03-16-06.


• **Bendikson K, Milki A, Speck-Zulak A and Westphal L (2003)** Comparison of GnRH antagonist cycles with and without oral contraceptive pill pretreat-ment in poor responders. Fertil Steril 80(Suppl. 3), s188.


• **Borm G, Mannaerts B.** Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000;15:1490–8.


• **Centers for Disease Control and Prevention (2006).** Assisted Reproductive Technology (ART) Report: 2005 Preliminary Clinic Data by State and National Summary. Available online:

• **Chappel and howles c.(1991):** re_evaluation of the role of luteinizing hormones and follicle_stimulating hormones in the ovulatory process: ultimately surges of lh . HUM. Repod 6:1206_1212.

• **Chen TH, Chang SP, Tsai CF, Juang KD:** Prevalence of depressive and anxiety disorders in an assisted reproductive technique clinic. Hum Reprod **2004**, 19:2313-2318.


• **De Jong D, Macklon NS and Fauser BC (2000)** A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the 'follicle-stimulating hormone window' combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertil Steril 73,1051-1054.
References


• **Fauser BC (1998)**: Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Hum Reprod 13(Suppl 3): 36-16.


• **Felberbaum R and Diedrich K (2000):** Ovarian stimulation of invitro fertilization and intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists. Hum Reprod; 14 (suppl.1):2072.


• **Germond M, Urner F, Chanson A, Primi MP, Wirthner D and Senn A (2004)** What is the most relevant standard of success in assisted reproduction?: the cumulated singleton/twin delivery rates per oocyte pick-up: the CUSIDERA and CUTWIDERA. Hum Reprod 19,2442-2444.

• **Gerris J, De Neubourg D, De Sutter P.** Cryopreservation as a tool to reduce multiple birth. Reprod Biomed Online **2003;7:**286 – 294.


References


• **Hohmann FP, Laven JS, de Jong FH, Eijkemans MJ and Fauser BC (2001)** Low-dose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development. Hum Reprod 16,846-854.

• **Hohmann FP, Macklon NS and F1auser BC (2003)** A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recom-binant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 88,166-173.

• **Holland F, Fishman L, Costigan DC, Luna L, Leeder S (1986)**: pharmacokinetic characteristics of the gonadotropin releasing hormone analogue D-Ser (TBU)-6EA-10 luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. J Clin Endocrinol Metab; 63:1065-1070.


• **Jones JS (1989):** Use of purified gonadotropins for ovarian stimulation in IVF, New Clinical Issues in Vitro fertilization clinics .in Obstetrics and Gynecology (12) 4. 775- 784.


• **Karten M.J Rivier J.E (1986):** Gonadotropin-releasing hormone analog design, Structure-function studies toward the development of agonist and antagonists and antagonists: rationale and perspective Endocr Rev. 7: 44 - 46.


References


- Kolibianakis E, Zikopoulos K, Camus M, Tournaye H, Van Steirteghem A and Devroey P (2004b) Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation. Hum Reprod 19,2545-2549.


References


• Lie RT, Lyngstadaas A, Orstavik KH, Bakketeig LS, Jacobsen G, Tanbo T. Birth defects in children conceived by ICSI compared with children conceived by other IVF-methods; a meta-analysis. Int J
References


• **Lunenfeld B (2004)**: Historical perspectives in gonadotropin the


- **Min JK, Breheny SA, MacLachlan V and Healy DL (2004)** What is the most relevant standard of success in assisted reproduction? The singleton, term gestation, live birth rate per cycle initiated: the BEST endpoint for assisted reproduction. Hum Reprod 19,3-7.


References


References


• **Ragni G, Vegetti W, Baroni E, Colombo M, Arnoldi M, Lombroso G**


- Sallam HN. Physiology of reproduction. In: Infertility and Assisted Conception. 2nd edit. Salam, H.N,


- Schmidt GE, Kin MH, Mansour R, Torello L. Friedman CI:


References


- **Tanbo T, Dale PO, Kjeksjus E and Abyholm T. (1990):** Stiniulation with human menopausal gonadotropins versus follicle-stimulating


- **The European Orgalutran Study Group, Borm G, Mannaerts B**: Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000,15(7):1490-1498.
• **The Ganirelix Dose-Finding Study Group (1998)** A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotropin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 13,3023-3031.


• **Tiitinen A, Hyden-Granskog C and Gissler M (2004)** What is the most relevant standard of success in assisted reproduction?: the value of cryopreservation on cumulative pregnancy rates per single oocyte retrieval should not be forgotten. Hum Reprod 19,2439-2441.


References


• Wikland M, Bergh C, Borg K, Hillensjo T, Howles CM, Knutsson A,
References


References
